Literature DB >> 1849731

Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs.

R J MacFadyen1, K R Lees, J L Reid.   

Abstract

1. There is a body of circumstantial and direct evidence supporting the existence and functional importance of a tissue based RAS at a variety of sites. 2. The relation between circulatory and tissue based systems is complex. The relative importance of the two in determining haemodynamic effects is unknown. 3. Despite the wide range of ACE inhibitors already available, it remains unclear whether there are genuine differences related to tissue specificity. 4. Pathological states such as chronic cardiac failure need to be explored with regard to the contribution of tissue based ACE activities in generating acute and chronic haemodynamic responses to ACE inhibitors. 5. The role of tissue vs plasma ACE activity may be clarified by study of the relation between drug concentration and haemodynamic effect, provided that the temporal dissociation is examined and linked to circulating and tissue based changes in ACE activity, angiotensin peptides and sympathetic hormones.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1849731      PMCID: PMC1368406          DOI: 10.1111/j.1365-2125.1991.tb03851.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  173 in total

1.  Hydrolysis of a synthetic angiotensin-converting enzyme substrate in dog lungs.

Authors:  J H Linehan; T A Bronikowski; D A Rickaby; C A Dawson
Journal:  Am J Physiol       Date:  1989-12

2.  Pharmacokinetics of an ACE inhibitor, S-9780, in man: evidence of tissue binding.

Authors:  K R Lees; A W Kelman; J L Reid; B Whiting
Journal:  J Pharmacokinet Biopharm       Date:  1989-10

3.  Metabolism and production of angiotensin I in different vascular beds in subjects with hypertension.

Authors:  P J Admiraal; F H Derkx; A H Danser; H Pieterman; M A Schalekamp
Journal:  Hypertension       Date:  1990-01       Impact factor: 10.190

4.  ACE inhibition with cilazapril improves myocardial perfusion to the ischemic regions during exercise: a pilot study.

Authors:  S Gasic; R Dudczak; A Korn; C Kleinbloesem
Journal:  J Cardiovasc Pharmacol       Date:  1990-02       Impact factor: 3.105

5.  Angiotensin converting enzyme in the human basal forebrain and midbrain visualized by in vitro autoradiography.

Authors:  S Y Chai; J S McKenzie; M J McKinley; F A Mendelsohn
Journal:  J Comp Neurol       Date:  1990-01-08       Impact factor: 3.215

6.  Estimation of regional metabolism and production of angiotensins in hypertensive subjects.

Authors:  M A Schalekamp; P J Admiraal; F H Derkx
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

7.  Antihypertensive and renal effects of captopril in relation to renin activity and bradykinin-induced vasodilation.

Authors:  W Kiowski; P van Brummelen; L Hulthén; F W Amann; F R Bühler
Journal:  Clin Pharmacol Ther       Date:  1982-06       Impact factor: 6.875

Review 8.  Pharmacokinetics of angiotensin converting enzyme inhibitors.

Authors:  M Burnier; B Waeber; J Nussberger; H R Brunner
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

Review 9.  Possible mechanism for the renoprotective effect of angiotensin converting enzyme inhibitors.

Authors:  L Raij; P J Shultz; J P Tolins
Journal:  J Hypertens Suppl       Date:  1989-09

10.  Relative inhibitory potency and plasma drug levels of angiotensin converting enzyme inhibitors in the rat.

Authors:  C I Johnston; R Cubela; B Jackson
Journal:  Clin Exp Pharmacol Physiol       Date:  1988-02       Impact factor: 2.557

View more
  8 in total

Review 1.  Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers: evidence for and against the combination in the treatment of hypertension and proteinuria.

Authors:  Niels Holmark Andersen; Carl Erik Mogensen
Journal:  Curr Hypertens Rep       Date:  2002-10       Impact factor: 5.369

2.  Studies with low dose intravenous diacid ACE inhibitor (perindoprilat) infusions in normotensive male volunteers.

Authors:  R J MacFadyen; K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1992-08       Impact factor: 4.335

3.  Attenuation by ACE inhibitor drugs of alpha-adrenoceptor sensitivity in human vessels: possible differences related to drug lipophilicity.

Authors:  M Kimura; K Umemura; K Kosuge; M Nishimoto; K Ohashi; M Nakashima
Journal:  Br J Clin Pharmacol       Date:  1998-12       Impact factor: 4.335

4.  Captopril augments both basal and frusemide-induced natriuresis in normal man by suppression of circulating angiotensin II.

Authors:  J G Motwani; A D Struthers
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

5.  Haemodynamic and hormonal responses to oral enalapril in salt depleted normotensive man.

Authors:  R J MacFadyen; H L Elliott; P A Meredith; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1993-03       Impact factor: 4.335

6.  Double blind controlled study of low dose intravenous perindoprilat or enalaprilat infusion in elderly patients with heart failure.

Authors:  R J MacFadyen; K R Lees; J L Reid
Journal:  Br Heart J       Date:  1993-04

7.  Responses to low dose intravenous perindoprilat infusion in salt deplete/salt replete normotensive volunteers.

Authors:  R J MacFadyen; K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1994-10       Impact factor: 4.335

8.  Chiropractic care for hypertension: Review of the literature and study of biological and genetic bases.

Authors:  Stephanie Gb Sullivan; Stefano Paolacci; Aysha Karim Kiani; Matteo Bertelli
Journal:  Acta Biomed       Date:  2020-11-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.